{"url_path":"/sec/cycn/8-k/2026-09-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-389318-index.html","accession_number":"0001193125-26-389318","cik":"0001755237","ticker":"CYCN","issuer_name":"Korsana Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1755237/0001193125-26-389318-index.html","primary_entity_key":"0001755237","primary_entity_name":"Korsana Biosciences, Inc."},"word_count":1449,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(a) Financial Statements of Business Acquired\n\nThe unaudited interim condensed consolidated financial statements of Korsana as of and for the six months ended June 30, 2026 and the related notes thereto are attached hereto as Exhibit 99.2 and are incorporated herein by reference.\n\nThe audited consolidated financial statements of Korsana as of December 31, 2025 and 2024 and for the year ended December 31, 2025 and for the period from November 8, 2024 (inception) to December 31, 2024 and the related notes thereto are included in the Proxy Statement/Prospectus beginning on page F-43 and are incorporated herein by reference.\n\n(b) Pro Forma Financial Information\n\nThe unaudited pro forma condensed combined financial information of Cyclerion and Korsana as of and for the six months ended June 30, 2026 and twelve months ended December 31, 2025 and the related notes thereto are attached hereto as Exhibit 99.4 and are incorporated herein by reference.\n\n \n\n(d) Exhibits\n\n \n\nExhibit\n\n  \n\nDescription\n\n2.1†\n  \n[Agreement and Plan of Merger and Reorganization, dated as of April 1, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC and Korsana Biosciences, Inc. (incorporated by reference to Exhibit 2.1 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on April 1, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex21.htm)\n\n2.2*\n  \n[Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of April 17, 2026, by and among Cyclerion Therapeutics, Inc., Cariboos Merger Sub Corp., Cariboos Merger Sub II, LLC and Korsana Biosciences, Inc.](d178159dex22.htm)\n\n3.1\n  \n[Restated Articles of Organization of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-230615), filed with the SEC on March 29, 2019).](http://www.sec.gov/Archives/edgar/data/1755237/000110465919018720/a19-7436_1ex4d1.htm)\n\n3.2\n  \n[Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., dated May 15, 2023 (incorporated by reference to Exhibit 3.1 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on May 15, 2023).](http://www.sec.gov/Archives/edgar/data/1755237/000114036123024768/brhc20052986_ex3-1.htm)\n\n3.3\n  \n[Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., dated May 19, 2023, designating the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on May 25, 2023).](http://www.sec.gov/Archives/edgar/data/1755237/000114036123026621/brhc20053546_ex3-1.htm)\n\n3.4*\n  \n[Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., effective September 8, 2026 (Reverse Stock Split).](d178159dex34.htm)\n\n3.5*\n  \n[Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc., effective September 8, 2026 (Name Change).](d178159dex35.htm)\n\n3.6*\n  \n[Articles of Amendment to the Restated Articles of Organization of Cyclerion Therapeutics, Inc. designating the Series B Non-Voting Convertible Preferred Stock, effective September 8, 2026.](d178159dex36.htm)\n\n3.7\n  \n[Amended and Restated Bylaws of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-8 (File No. 333-230615), filed with the SEC on March 29, 2019).](http://www.sec.gov/Archives/edgar/data/1755237/000110465919018720/a19-7436_1ex4d2.htm)\n\n4.1\n  \n[Form of Korsana Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-4 (File No. 333-295175), filed with the SEC on April 20, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex42.htm)\n\n4.2*\n  \n[Form of Merger Pre-Funded Warrant.](d178159dex42.htm)\n\n10.1\n  \n[Form of Korsana Support Agreement (incorporated by reference to Exhibit 10.1 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on April 1, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex101.htm)\n\n10.2\n  \n[Form of Cyclerion Support Agreement (incorporated by reference to Exhibit 10.2 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on April 1, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex102.htm)\n\n10.3\n  \n[Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.5 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on April 1, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex105.htm)\n\n10.4\n  \n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.3 to Cyclerion Therapeutics, Inc.’s Current Report on Form 8-K (File No. 001-38787), filed with the SEC on April 1, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275dex103.htm)\n\n \n\n10.5††*\n  \n[Contingent Value Rights Agreement, dated as of September 8, 2026, by and between Cyclerion Therapeutics, Inc. and Broadridge Corporate Issuer Solutions, LLC, as rights agent.](d178159dex105.htm)\n\n10.6*\n  \n[Form of Indemnification Agreement for directors and officers of the Company.](d178159dex106.htm)\n\n10.7#\n  \n[Korsana Biosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-4 (File No. 333-295175), filed with the SEC on April 20, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1019.htm)\n\n10.8#\n  \n[First Amendment to Korsana Biosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on July 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526299933/d111069dex1020.htm)\n\n10.9#*\n  \n[Korsana Biosciences, Inc. 2026 Stock Incentive Plan.](d178159dex109.htm)\n\n10.10#*\n  \n[Korsana Biosciences, Inc. 2026 Employee Stock Purchase Plan.](d178159dex1010.htm)\n\n10.11#\n  \n[Form of Stock Option Agreement under the Korsana Biosciences, Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-4 (File No. 333-295175), filed with the SEC on April 20, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1021.htm)\n\n10.12#\n  \n[Form of Restricted Stock Purchase Agreement of Korsana Biosciences, Inc. (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-4 (File No. 333-295175), filed with the SEC on April 20, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526162177/d111069dex1020.htm)\n\n10.13†††\n  \n[Paragon License Agreement, dated June 8, 2026, by and between Paragon Therapeutics, Inc. and Korsana Biosciences, Inc. (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on July 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526299933/d111069dex1030.htm)\n\n10.14†††\n  \n[Platform Option Agreement, effective as of October 16, 2025, by and among Paragon Therapeutics, Inc., Parasa Holding LLC and Korsana Biosciences, Inc. (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on June 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526263731/d111069dex1030.htm)\n\n10.15†††\n  \n[Paragon Research Letter Agreement, dated April 3, 2026, by and between Paragon Laboratories, Inc. and Korsana Biosciences, Inc. (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on June 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526263731/d111069dex1031.htm)\n\n10.16†††\n  \n[Cell Line License Agreement, effective as of December 2, 2024, by and between Korsana Biosciences, Inc. and WuXi Biologics Ireland Limited (incorporated by reference to Exhibit 10.32 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on June 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526263731/d111069dex1032.htm)\n\n10.17†††\n  \n[Amendment No. 1 to Cell Line License Agreement, effective as of March 2, 2026, by and between Korsana Biosciences, Inc. and WuXi Biologics Ireland Limited (incorporated by reference to Exhibit 10.33 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on June 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526263731/d111069dex1033.htm)\n\n10.18†††\n  \n[Biologics Master Services Agreement, dated as of December 12, 2024, by and between Korsana Biosciences, Inc. and WuXi Biologics (Hong Kong) Limited (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-4/A (File No. 333-295175), filed with the SEC on June 9, 2026).](http://www.sec.gov/Archives/edgar/data/1755237/000119312526263731/d111069dex1034.htm)\n\n10.19#*\n  \n[Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Jonathan Violin, Ph.D.](d178159dex1019.htm)\n\n \n\n10.20#*\n  \n[Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Mark Vignola, Ph.D.](d178159dex1020.htm)\n\n10.21#*\n  \n[Amended and Restated Offer Letter, dated as of September 8, 2026, by and between Korsana Biosciences, Inc. and Matthew Leoni, M.D.](d178159dex1021.htm)\n\n14.1*\n  \n[Code of Business Conduct and Ethics of Korsana Biosciences, Inc.](d178159dex141.htm)\n\n21.1*\n  \n[List of Subsidiaries of Korsana Biosciences, Inc.](d178159dex211.htm)\n\n99.1*\n  \n[Press Release, issued on September 8, 2026.](d178159dex991.htm)\n\n99.2*\n  \n[Unaudited Interim Condensed Consolidated Financial Statements of Korsana Biosciences, Inc. as of and for the six months ended June 30, 2026.](d178159dex992.htm)\n\n99.3*\n  \n[Management’s Discussion and Analysis of Financial Condition and Results of Operations of Korsana Biosciences, Inc. as of and for the six months ended June 30, 2026.](d178159dex993.htm)\n\n99.4*\n  \n[Unaudited Pro Forma Condensed Combined Financial Statements of Korsana Biosciences, Inc. and Cyclerion Therapeutics, Inc. as of and for the six months ended June 30, 2026 and the year ended December 31, 2025.](d178159dex994.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\n\nFiled herewith.\n\n#\n\nIndicates management contract or compensatory plan.\n\n†\n\nExhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.\n\n††\n\nPortions of this exhibit (indicated by “[***]”) have been omitted in accordance with the rules of the Securities and Exchange Commission.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nKorsana Biosciences, Inc.\n\n \n(Registrant)\n\nDate: September 11, 2026\n \nBy:\n \n\n/s/ Jonathan Violin\n\n \n\n \nName:\n \nJonathan Violin, Ph.D.\n\n \n\n \nTitle:\n \nChief Executive Officer and President"}